Datamonitor’s Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The G8 Pharmaceuticals market grew by 3% between 2005 and 2009 to reach a value of $497.6 billion
In 2014, the market is forecast to have a value of $563.7 billion, an increase of 2.5% from 2009.
The US is the world’s largest market and generates 55.6% of global revenues.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant annual average exchange rates.
CHAPTER 1 INTRODUCTION 19
1.1 What is this report about? 19
1.2 Who is the target reader? 19
1.3 How to use this report 19
1.4 Definitions 19
CHAPTER 2 GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK 20
CHAPTER 3 PHARMACEUTICALS IN CANADA 25
3.1 Market Overview 25
3.2 Market Value 26
3.3 Market Segmentation I 27
3.4 Market Segmentation II 28
3.5 Market Share 29
3.6 Five Forces Analysis 30
3.7 Leading Companies 38
3.8 Market Forecasts 49
3.9 Macroeconomic Indicators 50
CHAPTER 4 PHARMACEUTICALS IN FRANCE 52
4.1 Market Overview 52
4.2 Market Value 53
4.3 Market Segmentation I 54
4.4 Market Segmentation II 55
4.5 Market Share 56
4.6 Five Forces Analysis 57
4.7 Leading Companies 64
4.8 Market Forecasts 75
4.9 Macroeconomic Indicators 76
CHAPTER 5 PHARMACEUTICALS IN GERMANY 78
5.1 Market Overview 78
5.2 Market Value 79
5.3 Market Segmentation I 80
5.4 Market Segmentation II 81
5.5 Market Share 82
5.6 Five Forces Analysis 83
5.7 Leading Companies 90
5.8 Market Forecasts 100
5.9 Macroeconomic Indicators 101
CHAPTER 6 PHARMACEUTICALS IN ITALY 103
6.1 Market Overview 103
6.2 Market Value 105
6.3 Market Segmentation I 106
6.4 Market Segmentation II 107
6.5 Market Share 108
6.6 Five Forces Analysis 109
6.7 Leading Companies 116
6.8 Market Forecasts 125
6.9 Macroeconomic Indicators 126
CHAPTER 7 PHARMACEUTICALS IN JAPAN 128
7.1 Market Overview 128
7.2 Market Value 129
7.3 Market Segmentation I 130
7.4 Market Segmentation II 131
7.5 Market Share 132
7.6 Five Forces Analysis 133
7.7 Leading Companies 140
7.8 Market Forecasts 148
7.9 Macroeconomic Indicators 149
CHAPTER 8 PHARMACEUTICALS IN RUSSIA 151
8.1 Market Overview 151
8.2 Market Value 152
8.3 Market Segmentation I 153
8.4 Market Segmentation II 154
8.5 Market Share 155
8.6 Five Forces Analysis 156
8.7 Leading Companies 163
8.8 Market Forecasts 171
8.9 Macroeconomic Indicators 172
CHAPTER 9 PHARMACEUTICALS IN THE UNITED KINGDOM 174
9.1 Market Overview 174
9.2 Market Value 175
9.3 Market Segmentation I 176
9.4 Market Segmentation II 177
9.5 Market Share 178
9.6 Five Forces Analysis 179
9.7 Leading Companies 186
9.8 Market Forecasts 196
9.9 Macroeconomic Indicators 197
CHAPTER 10 PHARMACEUTICALS IN THE UNITED STATES 199
10.1 Market Overview 199
10.2 Market Value 200
10.3 Market Segmentation I 201
10.4 Market Segmentation II 202
10.5 Market Share 203
10.6 Five Forces Analysis 204
10.7 Leading Companies 211
10.8 Market Forecasts 224
10.9 Macroeconomic Indicators 225
CHAPTER 11 APPENDIX 226
11.1 Data Research Methodology 226
LIST OF TABLES
Table 1: G8 pharmaceuticals industry, revenue($bn) 2005–14 20
Table 2: G8 pharmaceuticals industry, revenue by country ($bn) 2005–09 22
Table 3: G8 pharmaceuticals industry forecast, revenue by country ($bn) 2009–14 24
Table 4: Canada Pharmaceuticals Market Value: $ billion, 2005-2009 26
Table 5: Canada Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 27
Table 6: Canada Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 28
Table 7: Canada Pharmaceuticals Market Share: % Share, by Value, 2009 29
Table 8: Key Facts: Pfizer 38
Table 9: Key Financials: Pfizer 40
Table 10: Key Facts: AstraZeneca PLC 41
Table 11: Key Financials: AstraZeneca PLC 43
Table 12: Key Facts: Apotex, Inc. 44
Table 13: Key Facts: Johnson & Johnson 46
Table 14: Key Financials: Johnson & Johnson 48
Table 15: Canada Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 49
Table 16: Canada Size of Population (million) , 2005-2009 50
Table 17: Canada GDP (Current Prices, $ billion), 2005-2009 50
Table 18: Canada Inflation, 2005-2009 51
Table 19: Canada Exchange Rate, 2005-2009 51
Table 20: France Pharmaceuticals Market Value: $ billion, 2005-2009 53
Table 21: France Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 54
Table 22: France Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 55
Table 23: France Pharmaceuticals Market Share: % Share, by Value, 2009 56
Table 24: Key Facts: AstraZeneca PLC 64
Table 25: Key Financials: AstraZeneca PLC 67
Table 26: Key Facts: Pfizer Inc. 68
Table 27: Key Financials: Pfizer Inc. 70
Table 28: Key Facts: GlaxoSmithKline Plc 71
Table 29: Key Financials: GlaxoSmithKline Plc 74
Table 30: France Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 75
Table 31: France Size of Population (million) , 2005-2009 76
Table 32: France GDP (Current Prices, $ billion), 2005-2009 76
Table 33: France Inflation, 2005-2009 77
Table 34: France Exchange Rate, 2005-2009 77
Table 35: Germany Pharmaceuticals Market Value: $ billion, 2005-2009 79
Table 36: Germany Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 80
Table 37: Germany Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 81
Table 38: Germany Pharmaceuticals Market Share: % Share, by Value, 2009 82
Table 39: Key Facts: Novartis AG 90
Table 40: Key Financials: Novartis AG 92
Table 41: Key Facts: Pfizer Inc. 93
Table 42: Key Financials: Pfizer Inc. 95
Table 43: Key Facts: GlaxoSmithKline Plc 96
Table 44: Key Financials: GlaxoSmithKline Plc 99
Table 45: Germany Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 100
Table 46: Germany Size of Population (million) , 2005-2009 101
Table 47: Germany GDP (Current Prices, $ billion), 2005-2009 101
Table 48: Germany Inflation, 2005-2009 102
Table 49: Germany Exchange Rate, 2005-2009 102
Table 50: Italy Pharmaceuticals Market Value: $ billion, 2005-2009 105
Table 51: Italy Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 106
Table 52: Italy Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 107
Table 53: Italy Pharmaceuticals Market Share: % Share, by Value, 2009 108
Table 55: Key Facts: Pfizer Inc. 118
Table 56: Key Financials: Pfizer Inc. 120
Table 59: Italy Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 125
Table 60: Italy Size of Population (million) , 2005-2009 126
Table 61: Italy GDP (Current Prices, $ billion), 2005-2009 126
Table 62: Italy Inflation, 2005-2009 127
Table 63: Italy Exchange Rate, 2005-2009 127
Table 64: Japan Pharmaceuticals Market Value: $ billion, 2005-2009 129
Table 65: Japan Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 130
Table 66: Japan Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 131
Table 67: Japan Pharmaceuticals Market Share: % Share, by Value, 2009 132
Table 71: Key Facts: Pfizer Inc. 145
Table 72: Key Financials: Pfizer Inc. 146
Table 73: Japan Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 148
Table 74: Japan Size of Population (million) , 2005-2009 149
Table 75: Japan GDP (Current Prices, $ billion), 2005-2009 149
Table 76: Japan Inflation, 2005-2009 150
Table 77: Japan Exchange Rate, 2005-2009 150
Table 78: Russia Pharmaceuticals Market Value: $ billion, 2005-2009 152
Table 79: Russia Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 153
Table 80: Russia Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 154
Table 81: Russia Pharmaceuticals Market Share: % Share, by Value, 2009 155
Table 82: Key Facts: Novartis AG 163
Table 83: Key Financials: Novartis AG 165
Table 84: Key Facts: Ranbaxy 166
Table 85: Key Financials: Ranbaxy 167
Table 86: Key Facts: Pharmstandard 168
Table 87: Key Facts: Chemie/Menarini 169
Table 88: Russia Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 171
Table 89: Russia Size of Population (million) , 2005-2009 172
Table 90: Russia GDP (Current Prices, $ billion), 2005-2009 172
Table 91: Russia Inflation, 2005-2009 173
Table 92: Russia Exchange Rate, 2005-2009 173
Table 93: United Kingdom Pharmaceuticals Market Value: $ billion, 2005-2009 175
Table 94: United Kingdom Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 176
Table 95: United Kingdom Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 177
Table 96: United Kingdom Pharmaceuticals Market Share: % Share, by Value, 2009 178
Table 97: Key Facts: Pfizer Inc. 186
Table 98: Key Financials: Pfizer Inc. 188
Table 99: Key Facts: GlaxoSmithKline Plc 189
Table 100: Key Financials: GlaxoSmithKline Plc 191
Table 101: Key Facts: AstraZeneca PLC 193
Table 102: Key Financials: AstraZeneca PLC 195
Table 103: United Kingdom Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 196
Table 104: United Kingdom Size of Population (million) , 2005-2009 197
Table 105: United Kingdom GDP (Current Prices, $ billion), 2005-2009 197
Table 106: United Kingdom Inflation, 2005-2009 198
Table 107: United Kingdom Exchange Rate, 2005-2009 198
Table 108: United States Pharmaceuticals Market Value: $ billion, 2005-2009 200
Table 109: United States Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 201
Table 110: United States Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 202
Table 111: United States Pharmaceuticals Market Share: % Share, by Value, 2009 203
Table 112: Key Facts: Pfizer 211
Table 113: Key Financials: Pfizer 213
Table 114: Key Facts: GlaxoSmithKline Plc 214
Table 115: Key Financials: GlaxoSmithKline Plc 217
Table 116: Key Facts: Merck & Co., Inc 218
Table 117: Key Financials: Merck & Co., Inc 220
Table 118: Key Facts: Johnson & Johnson 221
Table 119: Key Financials: Johnson & Johnson 223
Table 120: United States Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 224
Table 121: United States Size of Population (million) , 2005-2009 225
Table 122: United States GDP (Current Prices, $ billion), 2005-2009 225
Table 123: United States Inflation, 2005-2009 225
LIST OF FIGURES
Figure 1: G8 pharmaceuticals industry, revenue($bn) 2005–14 20
Figure 2: G8 Pharmaceuticals industry, revenue by country (%) 2009 21
Figure 3: G8 pharmaceuticals industry, revenue by country ($bn) 2005–09 22
Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($bn) 2009–14 23
Figure 5: Canada Pharmaceuticals Market Value: $ billion, 2005-2009 26
Figure 6: Canada Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 27
Figure 7: Canada Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 28
Figure 8: Canada Pharmaceuticals Market Share: % Share, by Value, 2009 29
Figure 9: Forces Driving Competition in the Pharmaceuticals Market in Canada, 2009 30
Figure 10: Drivers of Buyer Power in the Pharmaceuticals Market in Canada, 2009 32
Figure 11: Drivers of Supplier Power in the Pharmaceuticals Market in Canada, 2009 33
Figure 12: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Canada, 2009 34
Figure 13: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Canada, 2009 36
Figure 14: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Canada, 2009 37
Figure 15: Revenues & Profitability: Pfizer 40
Figure 16: Revenues & Profitability: AstraZeneca PLC 43
Figure 17: Revenues & Profitability: Johnson & Johnson 48
Figure 18: Canada Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 49
Figure 19: France Pharmaceuticals Market Value: $ billion, 2005-2009 53
Figure 20: France Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 54
Figure 21: France Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 55
Figure 22: France Pharmaceuticals Market Share: % Share, by Value, 2009 56
Figure 23: Forces Driving Competition in the Pharmaceuticals Market in France, 2009 57
Figure 24: Drivers of Buyer Power in the Pharmaceuticals Market in France, 2009 59
Figure 25: Drivers of Supplier Power in the Pharmaceuticals Market in France, 2009 60
Figure 26: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in France, 2009 61
Figure 27: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in France, 2009 62
Figure 28: Drivers of Degree of Rivalry in the Pharmaceuticals Market in France, 2009 63
Figure 29: Revenues & Profitability: AstraZeneca PLC 67
Figure 30: Revenues & Profitability: Pfizer Inc. 70
Figure 31: Revenues & Profitability: GlaxoSmithKline Plc 74
Figure 32: France Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 75
Figure 33: Germany Pharmaceuticals Market Value: $ billion, 2005-2009 79
Figure 34: Germany Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 80
Figure 35: Germany Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 81
Figure 36: Germany Pharmaceuticals Market Share: % Share, by Value, 2009 82
Figure 37: Forces Driving Competition in the Pharmaceuticals Market in Germany, 2009 83
Figure 38: Drivers of Buyer Power in the Pharmaceuticals Market in Germany, 2009 85
Figure 39: Drivers of Supplier Power in the Pharmaceuticals Market in Germany, 2009 86
Figure 40: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Germany, 2009 87
Figure 41: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Germany, 2009 88
Figure 42: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Germany, 2009 89
Figure 43: Revenues & Profitability: Novartis AG 92
Figure 44: Revenues & Profitability: Pfizer Inc. 95
Figure 45: Revenues & Profitability: GlaxoSmithKline Plc 99
Figure 46: Germany Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 100
Figure 47: Italy Pharmaceuticals Market Value: $ billion, 2005-2009 105
Figure 48: Italy Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 106
Figure 49: Italy Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 107
Figure 50: Italy Pharmaceuticals Market Share: % Share, by Value, 2009 108
Figure 51: Forces Driving Competition in the Pharmaceuticals Market in Italy, 2009 109
Figure 52: Drivers of Buyer Power in the Pharmaceuticals Market in Italy, 2009 111
Figure 53: Drivers of Supplier Power in the Pharmaceuticals Market in Italy, 2009 112
Figure 54: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Italy, 2009 113
Figure 55: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Italy, 2009 114
Figure 56: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Italy, 2009 115
Figure 57: Revenues & Profitability: Pfizer Inc. 120
Figure 59: Italy Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 125
Figure 60: Japan Pharmaceuticals Market Value: $ billion, 2005-2009 129
Figure 61: Japan Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 130
Figure 62: Japan Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 131
Figure 63: Japan Pharmaceuticals Market Share: % Share, by Value, 2009 132
Figure 64: Forces Driving Competition in the Pharmaceuticals Market in Japan, 2009 133
Figure 65: Drivers of Buyer Power in the Pharmaceuticals Market in Japan, 2009 135
Figure 66: Drivers of Supplier Power in the Pharmaceuticals Market in Japan, 2009 136
Figure 67: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Japan, 2009 137
Figure 68: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Japan, 2009 138
Figure 69: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Japan, 2009 139
Figure 71: Revenues & Profitability: Pfizer Inc. 147
Figure 72: Japan Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 148
Figure 73: Russia Pharmaceuticals Market Value: $ billion, 2005-2009 152
Figure 74: Russia Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 153
Figure 75: Russia Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 154
Figure 76: Russia Pharmaceuticals Market Share: % Share, by Value, 2009 155
Figure 77: Forces Driving Competition in the Pharmaceuticals Market in Russia, 2009 156
Figure 78: Drivers of Buyer Power in the Pharmaceuticals Market in Russia, 2009 158
Figure 79: Drivers of Supplier Power in the Pharmaceuticals Market in Russia, 2009 159
Figure 80: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Russia, 2009 160
Figure 81: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Russia, 2009 161
Figure 82: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Russia, 2009 162
Figure 83: Revenues & Profitability: Novartis AG 165
Figure 84: Revenues & Profitability: Ranbaxy 167
Figure 85: Russia Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 171
Figure 86: United Kingdom Pharmaceuticals Market Value: $ billion, 2005-2009 175
Figure 87: United Kingdom Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 176
Figure 88: United Kingdom Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 177
Figure 89: United Kingdom Pharmaceuticals Market Share: % Share, by Value, 2009 178
Figure 90: Forces Driving Competition in the Pharmaceuticals Market in the United Kingdom, 2009 179
Figure 91: Drivers of Buyer Power in the Pharmaceuticals Market in the United Kingdom, 2009 181
Figure 92: Drivers of Supplier Power in the Pharmaceuticals Market in the United Kingdom, 2009 182
Figure 93: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in the United Kingdom, 2009 183
Figure 94: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in the United Kingdom, 2009 184
Figure 95: Drivers of Degree of Rivalry in the Pharmaceuticals Market in the United Kingdom, 2009 185
Figure 96: Revenues & Profitability: Pfizer Inc. 188
Figure 99: United Kingdom Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 196
Figure 100: United States Pharmaceuticals Market Value: $ billion, 2005-2009 200
Figure 101: United States Pharmaceuticals Market Segmentation I: % Share, by Value, 2009 201
Figure 102: United States Pharmaceuticals Market Segmentation II: % Share, by Value, 2009 202
Figure 103: United States Pharmaceuticals Market Share: % Share, by Value, 2009 203
Figure 104: Forces Driving Competition in the Pharmaceuticals Market in the United States, 2009 204
Figure 105: Drivers of Buyer Power in the Pharmaceuticals Market in the United States, 2009 206
Figure 106: Drivers of Supplier Power in the Pharmaceuticals Market in the United States, 2009 207
Figure 107: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in the United States, 2009 208
Figure 108: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in the United States, 2009 209
Figure 109: Drivers of Degree of Rivalry in the Pharmaceuticals Market in the United States, 2009 210
Figure 110: Revenues & Profitability: Pfizer 213
Figure 114: United States Pharmaceuticals Market Value Forecast: $ billion, 2009-2014 224
Other selected research from the 'Canada' category:
Pharmaceuticals: Canada Industry Guide
OTC Pharmaceuticals - North America (NAFTA) Industry Guide
Other selected research from the 'France' category:
The eHealth Market in France: Assessing the Online Needs of Physicians and Consumers
OTC Pharmaceuticals in France
Other selected research from the 'Germany' category:
Personal Hygiene/ Personal Care: Germany Industry Guide
German Pharma Sector Analysis
Other selected research from the 'Italy' category:
The eHealth Market in Italy and Spain: Key Trends in Physician Channels of Influence
OTC Pharmaceuticals in Italy
Other selected research from the 'Japan' category:
The eHealth Market in Japan: Optimizing eHealth Tools for Reaching Consumers
Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
Other selected research from the 'Russia' category:
Russian Pharma Sector Forecast to 2013
OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide
Other selected research from the 'United Kingdom' category:
Pharmaceuticals - Global Group of Eight (G8) Industry Guide
Pharmaceuticals in the United Kingdom
Other selected research from the 'USA' category:
US Healthcare Sector Forecast to 2012
Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in US